Silo Pharma Inc - Asset Resilience Ratio
Silo Pharma Inc (SILO) has an Asset Resilience Ratio of 33.80% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Silo Pharma Inc's Asset Resilience Ratio has changed over time. Check Silo Pharma Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Silo Pharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Silo Pharma Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.37 Million | 33.8% |
| Total Liquid Assets | $2.37 Million | 33.80% |
Asset Resilience Insights
- Very High Liquidity: Silo Pharma Inc maintains exceptional liquid asset reserves at 33.80% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Silo Pharma Inc Industry Peers by Asset Resilience Ratio
Compare Silo Pharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Akero Therapeutics Inc
NASDAQ:AKRO |
Biotechnology | 55.87% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Silo Pharma Inc (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Silo Pharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 27.75% | $2.11 Million | $7.61 Million | -15.09pp |
| 2024-12-31 | 42.83% | $3.17 Million | $7.41 Million | -10.62pp |
| 2023-12-31 | 53.46% | $4.14 Million | $7.75 Million | +53.43pp |
| 2022-12-31 | 0.03% | $3.12K | $11.64 Million | -3.98pp |
| 2021-12-31 | 4.00% | $420.00K | $10.49 Million | +3.99pp |
| 2020-12-31 | 0.01% | $200.00 | $1.43 Million | -80.42pp |
| 2017-12-31 | 80.43% | $1.32 Million | $1.64 Million | -- |
About Silo Pharma Inc
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's … Read more